Global Biotechnological Drugs 麻豆原创 Research Report 2025

Publication ID:

PB502254711

Publication Date:

February 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Biotechnological Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Biotechnological Drugs, also known as biologics, are pharmaceutical products derived from living organisms using biotechnology techniques. These drugs can include vaccines, monoclonal antibodies, and gene therapies.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biotechnological Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biotechnological Drugs.
The Biotechnological Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biotechnological Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biotechnological Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
3SBIO
Anhui Anke Biotechnology
Beijing SL Pharmaceutical
Biotech Pharmaceutical
Cadila Healthcare
Celgen Biopharma
Celltrion
Dr Reddy鈥檚
GeneScience Pharmaceuticals
Hisun Pharma
Jiangsu Sihuan Bioengineering
Novartis (Sandoz)
Pfizer (Hospira)
Shanghai Lansheng Guojian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Tonghua Dongbao Pharmaceutical
Torrent Pharmaceuticals
Segment by Type
Genetically Engineered Drugs
Therapeutic Monoclonal Antibody Drugs
Gene Therapy and Nucleic Acid Drugs
Genetically Engineered Vaccines
Other
Segment by Application
Tumor
Autoimmune Disease
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biotechnological Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Biotechnological Drugs 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Genetically Engineered Drugs
1.2.3 Therapeutic Monoclonal Antibody Drugs
1.2.4 Gene Therapy and Nucleic Acid Drugs
1.2.5 Genetically Engineered Vaccines
1.2.6 Other
1.3 麻豆原创 by Application
1.3.1 Global Biotechnological Drugs 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Tumor
1.3.3 Autoimmune Disease
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biotechnological Drugs 麻豆原创 Perspective (2020-2031)
2.2 Global Biotechnological Drugs Growth Trends by Region
2.2.1 Global Biotechnological Drugs 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Biotechnological Drugs Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Biotechnological Drugs Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Biotechnological Drugs 麻豆原创 Dynamics
2.3.1 Biotechnological Drugs Industry Trends
2.3.2 Biotechnological Drugs 麻豆原创 Drivers
2.3.3 Biotechnological Drugs 麻豆原创 Challenges
2.3.4 Biotechnological Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biotechnological Drugs Players by Revenue
3.1.1 Global Top Biotechnological Drugs Players by Revenue (2020-2025)
3.1.2 Global Biotechnological Drugs Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Biotechnological Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biotechnological Drugs Revenue
3.4 Global Biotechnological Drugs 麻豆原创 Concentration Ratio
3.4.1 Global Biotechnological Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biotechnological Drugs Revenue in 2024
3.5 Global Key Players of Biotechnological Drugs Head office and Area Served
3.6 Global Key Players of Biotechnological Drugs, Product and Application
3.7 Global Key Players of Biotechnological Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biotechnological Drugs Breakdown Data by Type
4.1 Global Biotechnological Drugs Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Biotechnological Drugs Forecasted 麻豆原创 Size by Type (2026-2031)
5 Biotechnological Drugs Breakdown Data by Application
5.1 Global Biotechnological Drugs Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Biotechnological Drugs Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Biotechnological Drugs 麻豆原创 Size (2020-2031)
6.2 North America Biotechnological Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Biotechnological Drugs 麻豆原创 Size by Country (2020-2025)
6.4 North America Biotechnological Drugs 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biotechnological Drugs 麻豆原创 Size (2020-2031)
7.2 Europe Biotechnological Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Biotechnological Drugs 麻豆原创 Size by Country (2020-2025)
7.4 Europe Biotechnological Drugs 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biotechnological Drugs 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Biotechnological Drugs 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Biotechnological Drugs 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Biotechnological Drugs 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biotechnological Drugs 麻豆原创 Size (2020-2031)
9.2 Latin America Biotechnological Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Biotechnological Drugs 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Biotechnological Drugs 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biotechnological Drugs 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Biotechnological Drugs 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Biotechnological Drugs 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Biotechnological Drugs 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 3SBIO
11.1.1 3SBIO Company Details
11.1.2 3SBIO Business Overview
11.1.3 3SBIO Biotechnological Drugs Introduction
11.1.4 3SBIO Revenue in Biotechnological Drugs Business (2020-2025)
11.1.5 3SBIO Recent Development
11.2 Anhui Anke Biotechnology
11.2.1 Anhui Anke Biotechnology Company Details
11.2.2 Anhui Anke Biotechnology Business Overview
11.2.3 Anhui Anke Biotechnology Biotechnological Drugs Introduction
11.2.4 Anhui Anke Biotechnology Revenue in Biotechnological Drugs Business (2020-2025)
11.2.5 Anhui Anke Biotechnology Recent Development
11.3 Beijing SL Pharmaceutical
11.3.1 Beijing SL Pharmaceutical Company Details
11.3.2 Beijing SL Pharmaceutical Business Overview
11.3.3 Beijing SL Pharmaceutical Biotechnological Drugs Introduction
11.3.4 Beijing SL Pharmaceutical Revenue in Biotechnological Drugs Business (2020-2025)
11.3.5 Beijing SL Pharmaceutical Recent Development
11.4 Biotech Pharmaceutical
11.4.1 Biotech Pharmaceutical Company Details
11.4.2 Biotech Pharmaceutical Business Overview
11.4.3 Biotech Pharmaceutical Biotechnological Drugs Introduction
11.4.4 Biotech Pharmaceutical Revenue in Biotechnological Drugs Business (2020-2025)
11.4.5 Biotech Pharmaceutical Recent Development
11.5 Cadila Healthcare
11.5.1 Cadila Healthcare Company Details
11.5.2 Cadila Healthcare Business Overview
11.5.3 Cadila Healthcare Biotechnological Drugs Introduction
11.5.4 Cadila Healthcare Revenue in Biotechnological Drugs Business (2020-2025)
11.5.5 Cadila Healthcare Recent Development
11.6 Celgen Biopharma
11.6.1 Celgen Biopharma Company Details
11.6.2 Celgen Biopharma Business Overview
11.6.3 Celgen Biopharma Biotechnological Drugs Introduction
11.6.4 Celgen Biopharma Revenue in Biotechnological Drugs Business (2020-2025)
11.6.5 Celgen Biopharma Recent Development
11.7 Celltrion
11.7.1 Celltrion Company Details
11.7.2 Celltrion Business Overview
11.7.3 Celltrion Biotechnological Drugs Introduction
11.7.4 Celltrion Revenue in Biotechnological Drugs Business (2020-2025)
11.7.5 Celltrion Recent Development
11.8 Dr Reddy鈥檚
11.8.1 Dr Reddy鈥檚 Company Details
11.8.2 Dr Reddy鈥檚 Business Overview
11.8.3 Dr Reddy鈥檚 Biotechnological Drugs Introduction
11.8.4 Dr Reddy鈥檚 Revenue in Biotechnological Drugs Business (2020-2025)
11.8.5 Dr Reddy鈥檚 Recent Development
11.9 GeneScience Pharmaceuticals
11.9.1 GeneScience Pharmaceuticals Company Details
11.9.2 GeneScience Pharmaceuticals Business Overview
11.9.3 GeneScience Pharmaceuticals Biotechnological Drugs Introduction
11.9.4 GeneScience Pharmaceuticals Revenue in Biotechnological Drugs Business (2020-2025)
11.9.5 GeneScience Pharmaceuticals Recent Development
11.10 Hisun Pharma
11.10.1 Hisun Pharma Company Details
11.10.2 Hisun Pharma Business Overview
11.10.3 Hisun Pharma Biotechnological Drugs Introduction
11.10.4 Hisun Pharma Revenue in Biotechnological Drugs Business (2020-2025)
11.10.5 Hisun Pharma Recent Development
11.11 Jiangsu Sihuan Bioengineering
11.11.1 Jiangsu Sihuan Bioengineering Company Details
11.11.2 Jiangsu Sihuan Bioengineering Business Overview
11.11.3 Jiangsu Sihuan Bioengineering Biotechnological Drugs Introduction
11.11.4 Jiangsu Sihuan Bioengineering Revenue in Biotechnological Drugs Business (2020-2025)
11.11.5 Jiangsu Sihuan Bioengineering Recent Development
11.12 Novartis (Sandoz)
11.12.1 Novartis (Sandoz) Company Details
11.12.2 Novartis (Sandoz) Business Overview
11.12.3 Novartis (Sandoz) Biotechnological Drugs Introduction
11.12.4 Novartis (Sandoz) Revenue in Biotechnological Drugs Business (2020-2025)
11.12.5 Novartis (Sandoz) Recent Development
11.13 Pfizer (Hospira)
11.13.1 Pfizer (Hospira) Company Details
11.13.2 Pfizer (Hospira) Business Overview
11.13.3 Pfizer (Hospira) Biotechnological Drugs Introduction
11.13.4 Pfizer (Hospira) Revenue in Biotechnological Drugs Business (2020-2025)
11.13.5 Pfizer (Hospira) Recent Development
11.14 Shanghai Lansheng Guojian Pharmaceutical
11.14.1 Shanghai Lansheng Guojian Pharmaceutical Company Details
11.14.2 Shanghai Lansheng Guojian Pharmaceutical Business Overview
11.14.3 Shanghai Lansheng Guojian Pharmaceutical Biotechnological Drugs Introduction
11.14.4 Shanghai Lansheng Guojian Pharmaceutical Revenue in Biotechnological Drugs Business (2020-2025)
11.14.5 Shanghai Lansheng Guojian Pharmaceutical Recent Development
11.15 Shenzhen Neptunus Interlong Bio-Technique
11.15.1 Shenzhen Neptunus Interlong Bio-Technique Company Details
11.15.2 Shenzhen Neptunus Interlong Bio-Technique Business Overview
11.15.3 Shenzhen Neptunus Interlong Bio-Technique Biotechnological Drugs Introduction
11.15.4 Shenzhen Neptunus Interlong Bio-Technique Revenue in Biotechnological Drugs Business (2020-2025)
11.15.5 Shenzhen Neptunus Interlong Bio-Technique Recent Development
11.16 Tonghua Dongbao Pharmaceutical
11.16.1 Tonghua Dongbao Pharmaceutical Company Details
11.16.2 Tonghua Dongbao Pharmaceutical Business Overview
11.16.3 Tonghua Dongbao Pharmaceutical Biotechnological Drugs Introduction
11.16.4 Tonghua Dongbao Pharmaceutical Revenue in Biotechnological Drugs Business (2020-2025)
11.16.5 Tonghua Dongbao Pharmaceutical Recent Development
11.17 Torrent Pharmaceuticals
11.17.1 Torrent Pharmaceuticals Company Details
11.17.2 Torrent Pharmaceuticals Business Overview
11.17.3 Torrent Pharmaceuticals Biotechnological Drugs Introduction
11.17.4 Torrent Pharmaceuticals Revenue in Biotechnological Drugs Business (2020-2025)
11.17.5 Torrent Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

3SBIO
Anhui Anke Biotechnology
Beijing SL Pharmaceutical
Biotech Pharmaceutical
Cadila Healthcare
Celgen Biopharma
Celltrion
Dr Reddy鈥檚
GeneScience Pharmaceuticals
Hisun Pharma
Jiangsu Sihuan Bioengineering
Novartis (Sandoz)
Pfizer (Hospira)
Shanghai Lansheng Guojian Pharmaceutical
Shenzhen Neptunus Interlong Bio-Technique
Tonghua Dongbao Pharmaceutical
Torrent Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.